Premium
Prohibitin deficiency blocks proliferation and induces apoptosis in human hepatoma cells: Molecular mechanisms and functional implications
Author(s) -
SánchezQuiles Virginia,
Santamaría Enrique,
Segura Víctor,
Sesma Laura,
Prieto Jesús,
Corrales Fernando J.
Publication year - 2010
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.200900757
Subject(s) - prohibitin , microbiology and biotechnology , biology , gene silencing , apoptosis , proteasome , stable isotope labeling by amino acids in cell culture , mitochondrion , proteomics , cancer research , biochemistry , gene
Prohibitin is a multifunctional protein participating in a plethora of essential cellular functions, such as cell signaling, apoptosis, survival and proliferation. In the liver, deficient prohibitin activity participates in the progression of non‐alcoholic steatohepatitis and obesity, according to mechanisms that still must be elucidated. In this study, we have used a combination of transcriptomics and proteomics technologies to investigate the response of human hepatoma PLC/PRF/5 cells to prohibitin silencing to define in detail the biological function of hepatic Phb1 and to elucidate potential prohibitin‐dependent mechanisms participating in the maintenance of the transformed phenotype. Abrogation of prohibitin reduced proliferation and induced apoptosis in human hepatoma cells in a mechanism dependent on NFκB signaling. Moreover, down‐regulation of ERp29 together with down‐regulation of Erlin 2 suggests ER stress. In agreement, increased C/EBP homologous protein levels, poly‐ADP ribose polymerase cleavage and activation of caspase 12 and downstream caspase 7 evidenced ER stress‐induced apoptosis. Down‐regulation of proteasome activator complex subunit 2 and stathmin as well as accumulation of ubiquitinated proteins suggest interplay between ER stress and proteasome malfunction. Taken together, our results provide evidences for prohibitin having a central role in the maintenance of the transformed and invasive phenotype of human hepatoma cells and may further support previous studies suggesting prohibitin as a potential clinical target.